Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Alternative Bio Lands $15 Million to Develop Oncology Drugs based on Novel Enzymes

publication date: Dec 15, 2022

Alternative Bio raised $15 million in a seed round to develop a novel class of post-translational modifying enzymes as cancer treatments. The company’s technology is based on the work of three well-known academics in biomedical health with expertise in the areas of signaling, gene expression regulation, cancer biology and drug discovery. ABio has an innovative discovery platform to advance candidates that are aimed at some of the world’s most intractable cancers. The seed round was co-led by three China investors: Eight Roads Ventures, F-Prime Capital and Sequoia China Seed Fund. More details....

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital